Atea Pharmaceuticals
Founded Year
2012Stage
IPO | IPOTotal Raised
$283.43MDate of IPO
10/30/2020About Atea Pharmaceuticals
Atea Pharmaceuticals (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company that discovers and develops therapies to address the unmet medical needs of patients with life-threatening viral diseases.
Missing: Atea Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Atea Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Atea Pharmaceuticals
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Atea Pharmaceuticals in 1 CB Insights research brief, most recently on Jul 14, 2020.
Expert Collections containing Atea Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Atea Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Atea Pharmaceuticals Patents
Atea Pharmaceuticals has filed 27 patents.
The 3 most popular patent topics include:
- Carbamates
- Cyclopropanes
- Experimental drugs
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
3/5/2019 | 3/16/2021 | Viral plant pathogens and diseases, Viral diseases, Hemorrhagic fevers, Animal virology, Animal viral diseases | Grant |
Application Date | 3/5/2019 |
---|---|
Grant Date | 3/16/2021 |
Title | |
Related Topics | Viral plant pathogens and diseases, Viral diseases, Hemorrhagic fevers, Animal virology, Animal viral diseases |
Status | Grant |
Latest Atea Pharmaceuticals News
May 1, 2023
Boston, Massachusetts, UNITED STATES BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2023, and to provide a business update. To access the live conference call, participants may register here . The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com . To participate via telephone, please register in advance here . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archive of the audio webcast will be available on Atea Pharmaceuticals’ website approximately two hours after the conference call and will remain available for at least 90 days following the event. About Atea Pharmaceuticals Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea is developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates through using its internal discovery capabilities augmented by in-licensing. Currently, Atea is focused on the development of orally-available antiviral agents for serious viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C virus (HCV). For more information, please visit www.ateapharma.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing of Atea’s earnings call for the quarter ended March 31, 2023. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Contacts
Atea Pharmaceuticals Frequently Asked Questions (FAQ)
When was Atea Pharmaceuticals founded?
Atea Pharmaceuticals was founded in 2012.
Where is Atea Pharmaceuticals's headquarters?
Atea Pharmaceuticals's headquarters is located at 125 Summer Street, Boston.
What is Atea Pharmaceuticals's latest funding round?
Atea Pharmaceuticals's latest funding round is IPO.
How much did Atea Pharmaceuticals raise?
Atea Pharmaceuticals raised a total of $283.43M.
Who are the investors of Atea Pharmaceuticals?
Investors of Atea Pharmaceuticals include Sectoral Asset Management, Redmile Group, Bain Capital, Ally Bridge Group, Rock Springs Capital and 9 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.